臨床検査53巻13号

2009年12月発行

今月の主題 前立腺癌 各論 〈各種診断法〉

PSA以外の腫瘍マーカー

著者： 桶川隆嗣¹

所属機関： ¹杏林大学医学部泌尿器科

ページ範囲：P.1660 - P.1666

　前立腺癌の診断では血清PSA値が導入されて早期癌発見につながり，多大な貢献を果たしてきた．一方，PSAのバイオマーカーとしての限界が明らかになってきた．診断，予後予測の面で特異性が高く汎用性に優れたバイオマーカーが必要である．近年の技術革新と研究の進展，データーベースの向上により，有望なバイオマーカーが報告されている．最近，米国食品医薬品局(Food and Drug Administration；FDA)では，転移性前立腺癌におけるCellSearch Systemよる末梢血循環癌細胞(circulating tumor cells；CTC)の臨床診断の使用を許可し臨床の場で使用されている．

参考文献

1) Su SL, Huang IP, Fair WR, et al：Alternatively spliced variants of prostate-specific membrane antigen RNA：ratio of expression as a potential measurement of progression. Cancer Res　55：1441-1443, 1995

2) Horoszewicz JS, Kawinski E, Murphy GP：Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res　7：927-935, 1987

3) Xiao Z, Adam BL, Cazares LH, et al：Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res　61：6029-6033, 2001

4) Moorghen M, Cairns J, Forrester LM, et al：Enhanced expression of glutathione S-transferases in colorectal carcinoma compared to non-neoplastic mucosa. Carcinogenesis　12：13-17, 1991

5) Goessl C, Müller M, Heicappell R, et al：DNA-based detection of prostate cancer in urine after prostatic massage. Urology　58：335-338, 2001

6) Gonzalgo ML, Pavlovich CP, Lee SM, et al：Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res　9：2673-2677. 2003

7) Kuzmin I, Gillespie JW, Protopopov A, et al：The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res　62：3498-3502, 2002

8) Liu L, Yoon JH, Dammann R, et al：Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene　21：6835-6840, 2002

9) Luo J, Zha S, Gage WR, et al：Alpha-methylacyl-CoA racemase：a new molecular marker for prostate cancer. Cancer Res　62：2220-2226, 2002

10) Rogers CG, Yan G, Zha S, et al：Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol　172：1501-1503, 2004

11) Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al：a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res　59：5975-5979, 1999

12) de Kok JB, Verhaegh GW, Roelofs RW, et al：DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res　62：2695-2698, 2002

13) Hessels D, Klein Gunnewiek JM, van Oort I, et al：DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol　44：8-15, 2003

14) Suzuki H, Akakura K, Igarashi T, et al：Clinical usefulness of serum antip53 antibodies for prostate cancer detection：a comparative study with prostate specific antigen parameters. J Urol　171：182-618, 2004

15) Freedland SJ, de Gregorio F, Sacoolidge JC, et al：Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. Urology　61：1187-1192, 2003

16) Cairns P, Okami K, Halachmi S, et al：Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res　57：4997-5000, 1997

17) Shariat SF, Shalev M, Menesses-Diaz A, et al：Preoperative plasma levels of transforming growth factor beta(1)(TGF-beta(1))strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol　19：2856-2864, 2001

18) Li R, Wheeler T, Dai H, et al：High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate：cancer patients treated with radical prostatectomy. Am J Surg Pathol　28：928-934, 2004

19) Zeng Y, Opeskin K, Baldwin ME, et al：Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res　10：5137-5144, 2004

20) Okegawa T, Nutahara K, Higashihara E：Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J Urol　180：1342-1347, 2008

21) Okegawa T, Nutahara K, Higashihara E：Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol　181：1091-1097, 2009

22) de Bono JS, Scher HI, Montgomery RB, et al：Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res　14：6302-6309, 2008

23) Chen Bt, Loberg RD, Neeley CK, et al：Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology　65：616-621, 2005

24) Moreno JG, Miller MC, Gross S, et al：Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology　65：713-718, 2005

25) Danila DC, Heller G, Gignac GA, et al：Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res　13：7053-7058, 2007

26) Olmos D, Arkenau HT, Ang JE, et al：Circulating tumour cell(CTC)counts as intermediate end points in castration-resistant prostate cancer(CRPC):a single-centre experience. Ann Oncol　20：27-33, 2009

27) Scher HI, Jia X, de Bono JS, et al：Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer：a reanalysis of IMMC38 trial data. Lancet Oncol　10：233-239, 2009